Abstract 2076P
Background
Hand foot syndrome is a distinct side effect associated with capecitabine. Celecoxib, a cyclooxygenase (COX 2) inhibitor is the only drug effective in randomized trials. However, its use in clinics has declined due to concerns regarding cardiac safety. In our trial, we describe the use of topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy.
Methods
The D torch trial randomized 264 patients with breast or GI cancers receiving capecitabine to apply either 1% topical diclofenac or placebo gel. Stratified permuted variable size block randomization was done using a computer-generated random numbers sequence. The primary objective was to compare the incidence of grade 2 or higher HFS in diclofenac and placebo arms. Secondary objectives were incidence of any grade HFS, capecitabine dose reduction due to HFS and adherence with application. Here, we report the results of the monotherapy subgroup.
Results
108 out of 264 patients received capecitabine monotherapy (56 in diclofenac arm and 52 in placebo arm). Baseline characteristics were well matched in both arms. The study group’s median age was 47 years (IQR 39.5-57.5). Majority were females (n=101, 93.5%). 67 patients (62%) had an ECOG performance status of 0-1, while the rest were PS 2. 95 patients (87.9%) had carcinoma breast and the remaining 13 patients had various gastrointestinal cancers. 63 patients (58.9%) and 41 patients (38.3%) had stage 3 and 4 disease respectively, whereas only 3 patients (2.8%) had stage 2 cancer. Overall, 12 patients developed grade 2 or higher hand foot syndrome, of which 2 were in diclofenac group and 10 were in placebo group (3.6% vs 19.2%, p=0.01). Any grade HFS was seen in 3 patients (5.4%) in diclofenac arm and 12 patients (23%) in placebo arm (p=0.008). Dose reductions of capecitabine were less frequent in the diclofenac arm compared to placebo (3.6% vs 19.2% p=0.01). Adherence to topical treatment was more in the diclofenac group compared to placebo (93.2% vs 82.2%, p=0.04).
Conclusions
Topical diclofenac gel significantly reduced the incidence of HFS in patients receiving capecitabine monotherapy. Topical diclofenac gel application led to less frequent dose reductions of capecitabine.
Clinical trial identification
CTRI/2021/01/030592 (Clinical Trials Registry of India).
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Alkem Laboratories.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2116P - Preoperative body mass index, waist circumference, and mortality after major cancer surgery: A nationwide cohort study in South Korea
Presenter: Jiwon Yoon
Session: Poster session 06
2117P - Dietary patterns and clinical outcomes in patients with lung cancer: What needs to change
Presenter: Imanuely Borchardt
Session: Poster session 06
2118P - Refeeding syndrome: A prospective analysis in adults admitted to an oncology hospital
Presenter: Filipe Gonçalves
Session: Poster session 06
2119P - The prognostic impact of nutritional assessment and scores in advanced gastric cancer
Presenter: Sara Torresan
Session: Poster session 06
2120P - Nutritional deficiency post gastric cancer surgery
Presenter: Abay Makishev
Session: Poster session 06
2121P - Association between nutritional status and adverse events in gastrointestinal cancer patients undergoing outpatient chemotherapy in Japan
Presenter: Naoko Sato
Session: Poster session 06
2122P - Clinical significance of oncology patients’ nutritional status assessment
Presenter: Efthymios Kostaridis
Session: Poster session 06
2123P - Value of immuno-nutritional scores in the prognosis of hospitalised patients with lung cancer
Presenter: Jesús López
Session: Poster session 06
2124P - The impact of NUTRItional status at first medical oncology visit ON Clinical Outcomes: The NUTRIONCO study
Presenter: Maurizio Muscaritoli
Session: Poster session 06
2125P - Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study
Presenter: Alessio Cortellini
Session: Poster session 06